Identification | Back Directory | [Name]
1-(4-Methoxyphenyl)-6-(4-iodophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester | [CAS]
473927-64-9 | [Synonyms]
Apixaban IV Apixaban Impurity 107 AXN-IIIQ: What is
AXN-III Q: What is the CAS Number of
AXN-III Ethyl 6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine Ethyl 6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3- ethyl 6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate 1-(4-Methoxyphenyl)-6-(4-iodophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxyli 6-(4-iodophenyl)-1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate Ethyl 6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate 1-(4-Methoxyphenyl)-6-(4-iodophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl este 1-(4-Methoxyphenyl)-6-(4-iodophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester 1H-Pyrazolo[3,4-c]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydro-6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-, ethyl ester | [EINECS(EC#)]
200-258-5 | [Molecular Formula]
C22H20IN3O4 | [MDL Number]
MFCD19442850 | [MOL File]
473927-64-9.mol | [Molecular Weight]
517.32 |
Chemical Properties | Back Directory | [Boiling point ]
649.4±55.0 °C(Predicted) | [density ]
1.60 | [storage temp. ]
2-8°C(protect from light) | [pka]
-0.78±0.20(Predicted) | [Appearance]
Off-white to yellow Solid |
Hazard Information | Back Directory | [Uses]
Ethyl 6-(4-Iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate is an intermediate of Apixaban (A726700), a potent, direct, selective, and orally active inhibitor of coagulation factor Xa. It is a potential new oral coagulant that may be useful prevention of venous thromboembolism in total hip, knee replacement orthopedic surgery and stroke in treatment of patient with venous thromboembolic Jdisorder or with atrial fibrillation. | [Synthesis]
The reaction was carried out under inert atmosphere (argon). First, ethyl [(4-methoxyphenyl)hydrazinylidene]chloroacetate (14.1 g, 0.055 mol) was dissolved in 140 mL of ethyl acetate. The solution was cooled to 0-5 °C in an ice water bath. Under stirring conditions, 1-(4-iodophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one (21.1 g, 0.055 mol) was added in batches. Subsequently, triethylamine (11.1 g, 0.110 mol) was added slowly and dropwise at 0-5 °C. The reaction mixture was then cooled to a temperature of 0.5 °C. Cooling was stopped and the reaction mixture was allowed to warm up to room temperature. Next, the reaction mixture was heated to reflux and maintained at reflux for about 1 hour. The progress of the reaction was monitored by HPLC to ensure that the reaction was completed within 120 minutes. The reaction mixture was again cooled to 0-5 °C and a 1:1 hydrochloric acid solution diluted from concentrated hydrochloric acid (27.5 mL, 0.275 mol) with an equal volume of distilled water was slowly added dropwise. After cooling, the reaction mixture was continued to be stirred for about 1 hour. Then, 55 mL of water was added and the suspension formed was continued to be stirred under cooling conditions for 2 hours. The product was isolated by filtration and dried under vacuum at 50 °C for 24 h to afford 6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid (Product III) in a yield of 21.3 g, 75% yield, and 95% purity by HPLC. | [References]
[1] Patent: WO2014/75648, 2014, A1. Location in patent: Page/Page column 11 [2] Patent: WO2015/177801, 2015, A1. Location in patent: Page/Page column 23 |
|
|